A Mark Richards

Summary

Country: New Zealand

Publications

  1. doi request reprint Angiotensin-converting enzyme 2 A1075G polymorphism is associated with survival in an acute coronary syndromes cohort
    Barry R Palmer
    Department of Medicine, Christchurch Cardioendocrine Research Group, Christchurch School of Medicine and Health Sciences, University of Otago, Christchurch, New Zealand
    Am Heart J 156:752-8. 2008
  2. ncbi request reprint Four-day urocortin-I administration has sustained beneficial haemodynamic, hormonal, and renal effects in experimental heart failure
    Miriam T Rademaker
    Christchurch Cardioendocrine Research Group, Department of Medicine, The Christchurch School of Medicine and Health Sciences, PO Box 4345, Christchurch, New Zealand
    Eur Heart J 26:2055-62. 2005
  3. ncbi request reprint Urotensin II in the cardiovascular system
    A Mark Richards
    Christchurch Cardioendocrine Research Group, Department of Medicine, Christchurch School of Medicine and Health Sciences, Riccarton Avenue, P O Box 4345, Christchurch, New Zealand
    Peptides 25:1795-802. 2004
  4. ncbi request reprint Natriuretic peptides: update on Peptide release, bioactivity, and clinical use
    A Mark Richards
    Department of Medicine, Christchurch School of Medicine and Health Sciences, Christchurch, New Zealand
    Hypertension 50:25-30. 2007
  5. ncbi request reprint NT-proBNP in heart failure: therapy decisions and monitoring
    Mark Richards
    Christchurch Cardioendocrine Research Group, Department of Medicine, Christchurch School of Medicine and Health Sciences, P O Box 4345, Christchurch, New Zealand
    Eur J Heart Fail 6:351-4. 2004
  6. ncbi request reprint B-type natriuretic peptides and ejection fraction for prognosis after myocardial infarction
    A Mark Richards
    Christchurch Cardioendocrine Research Group, Christchurch School of Medicine and Health Sciences, PO Box 4345, Christchurch, New Zealand
    Circulation 107:2786-92. 2003
  7. ncbi request reprint Clinical applications of B-type natriuretic peptides
    A Mark Richards
    Christchurch Cardioendocrine Research Group, Christchurch School of Medicine and Health Sciences, P O Box 4345, Christchurch, New Zealand
    Trends Endocrinol Metab 15:170-4. 2004
  8. doi request reprint What we may expect from biomarkers in heart failure
    A Mark Richards
    National Heart Foundation of New Zealand, New Zealand
    Heart Fail Clin 5:463-70. 2009
  9. ncbi request reprint Comparison of B-type natriuretic peptides for assessment of cardiac function and prognosis in stable ischemic heart disease
    Mark Richards
    Christchurch Cardioendocrine Research Group, Christchurch Hospital, Christchurch, New Zealand
    J Am Coll Cardiol 47:52-60. 2006
  10. ncbi request reprint The natriuretic peptides in heart failure
    A Mark Richards
    Christchurch Cardioendocrine Research Group, Christchurch School of Medicine and Health Sciences, 4345 Christchurch, New Zealand
    Basic Res Cardiol 99:94-100. 2004

Detail Information

Publications108 found, 100 shown here

  1. doi request reprint Angiotensin-converting enzyme 2 A1075G polymorphism is associated with survival in an acute coronary syndromes cohort
    Barry R Palmer
    Department of Medicine, Christchurch Cardioendocrine Research Group, Christchurch School of Medicine and Health Sciences, University of Otago, Christchurch, New Zealand
    Am Heart J 156:752-8. 2008
    ..We tested the hypothesis that the rare allele of an ACE2 gene polymorphism was associated with risk factors for and adverse outcome after acute coronary syndrome (ACS) events...
  2. ncbi request reprint Four-day urocortin-I administration has sustained beneficial haemodynamic, hormonal, and renal effects in experimental heart failure
    Miriam T Rademaker
    Christchurch Cardioendocrine Research Group, Department of Medicine, The Christchurch School of Medicine and Health Sciences, PO Box 4345, Christchurch, New Zealand
    Eur Heart J 26:2055-62. 2005
    ..To investigate the subacute effects of a sustained intravenous infusion of urocortin-I (Ucn-I) in experimental heart failure (HF)...
  3. ncbi request reprint Urotensin II in the cardiovascular system
    A Mark Richards
    Christchurch Cardioendocrine Research Group, Department of Medicine, Christchurch School of Medicine and Health Sciences, Riccarton Avenue, P O Box 4345, Christchurch, New Zealand
    Peptides 25:1795-802. 2004
    ..The place of urotensin II in the chronic trophic responses to cardiac and vascular injury and its possible roles as a neurotransmitter and/or regulator of renal and endocrine function remain largely unexplored...
  4. ncbi request reprint Natriuretic peptides: update on Peptide release, bioactivity, and clinical use
    A Mark Richards
    Department of Medicine, Christchurch School of Medicine and Health Sciences, Christchurch, New Zealand
    Hypertension 50:25-30. 2007
  5. ncbi request reprint NT-proBNP in heart failure: therapy decisions and monitoring
    Mark Richards
    Christchurch Cardioendocrine Research Group, Department of Medicine, Christchurch School of Medicine and Health Sciences, P O Box 4345, Christchurch, New Zealand
    Eur J Heart Fail 6:351-4. 2004
    ..Finally, adjustment of therapy for heart failure according to serial measurements of NT-proBNP promises to improve outcomes in comparison with adjusting therapy according to unassisted clinical acumen...
  6. ncbi request reprint B-type natriuretic peptides and ejection fraction for prognosis after myocardial infarction
    A Mark Richards
    Christchurch Cardioendocrine Research Group, Christchurch School of Medicine and Health Sciences, PO Box 4345, Christchurch, New Zealand
    Circulation 107:2786-92. 2003
    ..After acute cardiac injury, left ventricular ejection fraction (LVEF) is also of prognostic significance and plays a major role in determining the therapeutic response...
  7. ncbi request reprint Clinical applications of B-type natriuretic peptides
    A Mark Richards
    Christchurch Cardioendocrine Research Group, Christchurch School of Medicine and Health Sciences, P O Box 4345, Christchurch, New Zealand
    Trends Endocrinol Metab 15:170-4. 2004
    ..Recombinant B-type NP is an effective parenteral treatment in decompensated heart failure. These applications of B-type NPs require confirmation before they become established in routine management of heart failure...
  8. doi request reprint What we may expect from biomarkers in heart failure
    A Mark Richards
    National Heart Foundation of New Zealand, New Zealand
    Heart Fail Clin 5:463-70. 2009
    ..Despite many promising candidates requiring fuller investigation, currently, only the natriuretic peptides satisfy these requirements...
  9. ncbi request reprint Comparison of B-type natriuretic peptides for assessment of cardiac function and prognosis in stable ischemic heart disease
    Mark Richards
    Christchurch Cardioendocrine Research Group, Christchurch Hospital, Christchurch, New Zealand
    J Am Coll Cardiol 47:52-60. 2006
    ....
  10. ncbi request reprint The natriuretic peptides in heart failure
    A Mark Richards
    Christchurch Cardioendocrine Research Group, Christchurch School of Medicine and Health Sciences, 4345 Christchurch, New Zealand
    Basic Res Cardiol 99:94-100. 2004
    ....
  11. ncbi request reprint Dendroaspis natriuretic peptide: endogenous or dubious?
    A Mark Richards
    Christchurch Cardioendocrine Research Group, Christchurch School of Medicine and Health Sciences, PO Box 4345, Christchurch, New Zealand
    Lancet 359:5-6. 2002
  12. doi request reprint Mineralocorticoid receptor antagonists for heart failure
    Arthur Mark Richards
    Cardioendocrine Research Group, University of Otago, Department of Medicine, PO Box 4345, Christchurch, New Zealand
    Expert Opin Pharmacother 12:2801-15. 2011
    ..With the recent publication of the landmark therapeutic trial (EMPHASIS), it is timely to review the appropriate use of these agents in heart failure...
  13. ncbi request reprint Health gains by using natriuretic peptides in diagnosis, prognosis and treatment
    Mark Richards
    Christchurch Cardioendocrine Research Group, Christchurch, New Zealand
    Scand J Clin Lab Invest Suppl 240:129-37. 2005
    ....
  14. doi request reprint Tailored therapy for heart failure: neurohormones
    A Mark Richards
    Department of Medicine, University of Otago, P O Box 4345, Christchurch, New Zealand
    Can J Physiol Pharmacol 89:603-7. 2011
    ....
  15. doi request reprint Urocortin 2 inhibits furosemide-induced activation of renin and enhances renal function and diuretic responsiveness in experimental heart failure
    Miriam T Rademaker
    Christchurch Cardioendocrine Research Group, Christchurch School of Medicine, Christchurch, New Zealand
    Circ Heart Fail 2:532-40. 2009
    ..Because any prospective new treatment is likely to be used in conjunction with standard diuretic therapy, it is necessary to investigate the combined effects of these agents...
  16. ncbi request reprint Long-term adrenomedullin administration in experimental heart failure
    Miriam T Rademaker
    Christchurch Cardioendocrine Research Group, Department of Medicine, The Christchurch School of Medicine, Christchurch, New Zealand
    Hypertension 40:667-72. 2002
    ..These findings support the concept of adrenomedullin as a protective hormone during hemodynamic compromise with therapeutic potential in heart failure...
  17. ncbi request reprint Apelin-13 induces a biphasic haemodynamic response and hormonal activation in normal conscious sheep
    Christopher J Charles
    Christchurch Cardioendocrine Research Group, Christchurch School of Medicine and Health Sciences, Christchurch, New Zealand
    J Endocrinol 189:701-10. 2006
    ..Apelin also increases circulating levels of a number of vasoactive hormones. Taken together, these results suggest a potential role for apelin in pressure/volume homeostasis...
  18. ncbi request reprint Urocortin 2 combined with angiotensin-converting enzyme inhibition in experimental heart failure
    Miriam T Rademaker
    Christchurch Cardioendocrine Research Group, Department of Medicine, Christchurch School of Medicine, Christchurch, New Zealand
    Clin Sci (Lond) 114:635-42. 2008
    ..These results indicate that dual treatment with these two agents is beneficial...
  19. ncbi request reprint Evaluation of AMPD1 C34T genotype as a predictor of mortality in heart failure and post-myocardial infarction patients
    Richard P Collins
    Christchurch Cardioendocrine Research Group, Department of Medicine, Christchurch School of Medicine and Health Sciences, PO Box 4345, Christchurch, New Zealand
    Am Heart J 152:312-20. 2006
    ..This study aimed to corroborate the association of the AMPD1 C34T polymorphism with survival in larger myocardial infarction (MI) and HF cohorts...
  20. doi request reprint Cardiac chymase converts rat proAngiotensin-12 (PA12) to angiotensin II: effects of PA12 upon cardiac haemodynamics
    Hamish C G Prosser
    School of Biological Sciences, University of Canterbury, PO Box 4800, Christchurch, New Zealand
    Cardiovasc Res 82:40-50. 2009
    ....
  21. doi request reprint Prolonged urocortin 2 administration in experimental heart failure: sustained hemodynamic, endocrine, and renal effects
    Miriam T Rademaker
    Christchurch Cardioendocrine Research Group, Department of Medicine, University of Otago, Christchurch, PO Box 4345, Christchurch, New Zealand
    Hypertension 57:1136-44. 2011
    ..These findings support the therapeutic potential for urocortin 2 in heart failure...
  22. pmc The contrasting relationships between betaine and homocysteine in two clinical cohorts are associated with plasma lipids and drug treatments
    Michael Lever
    Canterbury Health Laboratories, Clinical Biochemistry Unit, Christchurch, New Zealand
    PLoS ONE 7:e32460. 2012
    ..Urinary betaine excretion positively correlated with plasma homocysteine in outpatients attending a lipid disorders clinic (lipid clinic study). We aimed to confirm this in subjects with established vascular disease...
  23. ncbi request reprint Urocortin 2 infusion in healthy humans: hemodynamic, neurohormonal, and renal responses
    Mark E Davis
    Christchurch Cardioendocrine Research Group, Christchurch School of Medicine and Health Sciences, Christchurch, New Zealand
    J Am Coll Cardiol 49:461-71. 2007
    ..We sought to examine the effects of urocortin (UCN) 2 infusion on hemodynamic status, cardiovascular hormones, and renal function in healthy humans...
  24. ncbi request reprint Combined angiotensin-converting enzyme inhibition and adrenomedullin in an ovine model of heart failure
    Miriam T Rademaker
    Christchurch Cardioendocrine Research Group, Department of Medicine, The Christchurch School of Medicine, P O Box 4345, New Zealand
    Clin Sci (Lond) 102:653-60. 2002
    ..Despite the greater falls in blood pressure (and presumably renal perfusion pressure), renal function was maintained at a level similar to that observed with captopril alone...
  25. ncbi request reprint Hemodynamic, hormonal, and renal effects of (pro)renin receptor blockade in experimental heart failure
    Miriam T Rademaker
    Christchurch Heart Institute, University of Otago, Christchurch, New Zealand
    Circ Heart Fail 5:645-52. 2012
    ..The (pro)renin receptor (P)RR is implicated in blood pressure regulation and the pathophysiology of heart failure (HF). The effects of (P)RR blockade in HF have not been previously investigated...
  26. doi request reprint A common variant at chromosome 9P21.3 is associated with age of onset of coronary disease but not subsequent mortality
    Katrina L Ellis
    Christchurch Cardioendocrine Research Group, Department of Medicine, University of Otago Christchurch, Christchurch, New Zealand
    Circ Cardiovasc Genet 3:286-93. 2010
    ..However, the effect of rs1333049 on clinical outcomes in patients with established coronary disease has yet to be determined...
  27. doi request reprint Transforming growth factor-beta blockade down-regulates the renin-angiotensin system and modifies cardiac remodeling after myocardial infarction
    Leigh J Ellmers
    Christchurch Cardioendocrine Research Group, Department of Medicine, Christchurch School of Medicine and Health Sciences, Christchurch 8140, New Zealand
    Endocrinology 149:5828-34. 2008
    ..Our findings indicate that blockade of the TGF-beta signaling pathway results in significant amelioration of deleterious cardiac remodeling after infarction...
  28. ncbi request reprint Angiotensinogen M235T and T174M gene polymorphisms in combination doubles the risk of mortality in heart failure
    Anna P Pilbrow
    Cardioendocrine Research Group, Department of Medicine, Christchurch School of Medicine and Health Sciences, 2 Riccarton Avenue, PO Box 4345, Christchurch 8140, New Zealand
    Hypertension 49:322-7. 2007
    ..0; 95% CI: 1.3 to 3.0; P=0.001). This study suggested that angiotensinogen gene variants M235T and T174M may provide prognostic information for long-term survival in heart failure patients...
  29. pmc Influence of natriuretic peptide receptor-1 on survival and cardiac hypertrophy during development
    Nicola J A Scott
    Department of Medicine, University of Otago Christchurch, P O Box 4345, Christchurch, New Zealand
    Biochim Biophys Acta 1792:1175-84. 2009
    ..The decreased viability of Npr1(-/-)embryos may result from a combination of cardiomegaly and dysregulated Cx43 protein affecting cardiac contractility...
  30. doi request reprint Plasma aldosterone levels during hospitalization are predictive of survival post-myocardial infarction
    Barry R Palmer
    Department of Medicine, Christchurch Cardioendocrine Research Group, Christchurch School of Medicine and Health Sciences, University of Otago, Christchurch 8140, New Zealand
    Eur Heart J 29:2489-96. 2008
    ..We investigated whether aldosterone levels in patients presenting with STEMI or non-STEMI, are predictive of mortality during prolonged follow-up...
  31. ncbi request reprint Combined inhibition of angiotensin II and endothelin suppresses the brain natriuretic peptide response to developing heart failure
    Miriam T Rademaker
    Christchurch Cardioendocrine Research Group, Department of Medicine, The Christchurch School of Medicine, Christchurch, New Zealand
    Clin Sci (Lond) 106:569-76. 2004
    ....
  32. pmc Betaine and secondary events in an acute coronary syndrome cohort
    Michael Lever
    Clinical Biochemistry Unit, Canterbury Health Laboratories, Christchurch, New Zealand
    PLoS ONE 7:e37883. 2012
    ..Betaine insufficiency is associated with unfavourable vascular risk profiles in metabolic syndrome patients. We investigated associations between betaine insufficiency and secondary events in acute coronary syndrome patients...
  33. pmc The common G-866A polymorphism of the UCP2 gene and survival in diabetic patients following myocardial infarction
    Barry R Palmer
    Christchurch Cardioendocrine Research Group, Department of Medicine, University of Otago, Christchurch, PO Box 4345, Christchurch, New Zealand
    Cardiovasc Diabetol 8:31. 2009
    ..The association of UCP2 with baseline biochemical and hormonal measurements, including levels of the inflammatory marker myeloperoxidase, was also examined...
  34. ncbi request reprint Antecedent hypertension and heart failure after myocardial infarction
    A Mark Richards
    Cardiology, Christchurch Hospital, Christchurch, New Zealand
    J Am Coll Cardiol 39:1182-8. 2002
    ..We sought to assess the relationship of antecedent hypertension to neurohormones, ventricular remodeling and clinical heart failure (HF) after myocardial infarction (MI)...
  35. ncbi request reprint NTproBNP-guided drug treatment for chronic heart failure: design and methods in the "BATTLESCARRED" trial
    John G Lainchbury
    The Christchurch Cardioendocrine Research Group, Department of Medicine, The Christchurch School of Medicine and Health Sciences, University of Otago, Christchurch, New Zealand
    Eur J Heart Fail 8:532-8. 2006
    ..How best to decide when to introduce drugs and what doses are optimal in individual patients with chronic heart failure (CHF), is unclear...
  36. ncbi request reprint Hemodynamic, hormonal, and renal actions of adrenomedullin-2 in normal conscious sheep
    Christopher J Charles
    Christchurch Cardioendocrine Research Group, Christchurch School of Medicine and Health Sciences, New Zealand
    Endocrinology 147:1871-7. 2006
    ..Thus, AM-2 may be another important regulator of volume and pressure homeostasis and may play a role in the pathophysiology of heart disease...
  37. ncbi request reprint Urocortin 1 modulates the neurohumoral response to acute nitroprusside-induced hypotension in sheep
    Christopher J Charles
    Christchurch Cardioendocrine Research Group, Christchurch School of Medicine and Health Sciences, PO Box 4345, Christchurch, New Zealand
    Clin Sci (Lond) 112:485-91. 2007
    ..The threshold for the action of Ucn1 on the natriuretic peptides and endothelin-1 appears to be below that of other actions of Ucn1...
  38. ncbi request reprint Plasma concentrations of myeloperoxidase predict mortality after myocardial infarction
    Tessa J Mocatta
    Department of Pathology, Christchurch School of Medicine and Health Sciences, University of Otago, Christchurch, New Zealand
    J Am Coll Cardiol 49:1993-2000. 2007
    ..This study investigated relationships between plasma myeloperoxidase (MPO), protein oxidation markers, and clinical outcome retrospectively in patients after acute myocardial infarction (MI)...
  39. ncbi request reprint Urocortin 1 administration from onset of rapid left ventricular pacing represses progression to overt heart failure
    Miriam T Rademaker
    Department of Medicine, Christchurch School of Medicine, PO Box 4345, Christchurch, New Zealand
    Am J Physiol Heart Circ Physiol 293:H1536-44. 2007
    ..These data strongly support a use for Ucn1 as a therapeutic option early in the course of the disease...
  40. doi request reprint Effect of nutrition on plasma C-type natriuretic peptide forms in adult sheep: evidence for enhanced C-type natriuretic peptide degradation during caloric restriction
    Timothy C R Prickett
    Department of Medicine, Christchurch School of Medicine and Health Sciences, University of Otago, Christchurch, PO Box 4345, 8140 Christchurch, New Zealand
    Metabolism 59:796-801. 2010
    ..Fall in plasma CNP but not in NTproCNP in CR adult sheep suggests that CNP degradation (not synthesis) is altered, and contrasts with previous findings in growing lambs where CR reduces both CNP forms...
  41. doi request reprint Regional release and clearance of C-type natriuretic peptides in the human circulation and relation to cardiac function
    Suetonia C Palmer
    Department of Medicine, University of Otago Christchurch, Christchurch, New Zealand
    Hypertension 54:612-8. 2009
    ..Taken together, differences in magnitude and direction of transorgan gradients for CNP compared with NT-proCNP suggest net generalized cosecretion with differing mechanisms of clearance...
  42. ncbi request reprint Integrated hemodynamic, hormonal, and renal actions of urocortin 2 in normal and paced sheep: beneficial effects in heart failure
    Miriam T Rademaker
    Cardioendocrine Research Group, Christchurch School of Medicine, Christchurch, New Zealand
    Circulation 112:3624-32. 2005
    ..Urocortin 2 (Ucn2) has potent cardiovascular actions and may participate in the pathophysiology of heart failure (HF). The integrated hemodynamic, endocrine, and renal effects of Ucn2 are unknown...
  43. doi request reprint Renal and cardiac function for long-term (10 year) risk stratification after myocardial infarction
    Suetonia C Palmer
    Department of Medicine, University of Otago Christchurch, 2 Riccarton Avenue, Christchurch 8140, New Zealand
    Eur Heart J 30:1486-94. 2009
    ..7%, P < 0.001). Conclusion Ten year rates of mortality and HF are 5-10 times higher when lower eGFR is present together with increased NT-proBNP or depressed LVEF...
  44. ncbi request reprint Amino-terminal proCNP: a putative marker of cartilage activity in postnatal growth
    Timothy C R Prickett
    Department of Medicine, Christchurch School of Medicine and Health Sciences, Christchurch 8015, New Zealand
    Pediatr Res 58:334-40. 2005
    ..In summary, NT-proCNP levels in blood show a strong association with growth velocity and markers of bone formation and may well serve as a useful marker of growth plate activity in humans and other mammals...
  45. doi request reprint Effect of sex steroids on plasma C-type natriuretic peptide forms: stimulation by oestradiol in lambs and adult sheep
    Timothy C R Prickett
    Department of Medicine, University of Otago, PO Box 4345, Christchurch 8140, New Zealand
    J Endocrinol 199:481-7. 2008
    ..These results are the first to show that E(2) stimulates plasma CNP forms and bALP in lambs and adult sheep and raise the possibility that CNP also participates in bone formation in the mature skeleton...
  46. doi request reprint Hemodynamic, hormonal, and renal actions of adrenomedullin 2 in experimental heart failure
    Miriam T Rademaker
    Christchurch Cardioendocrine Research Group, University of Otago, Christchurch, New Zealand
    Circ Heart Fail 1:134-42. 2008
    ..The effects of AM2 in heart failure have not been investigated previously...
  47. ncbi request reprint Endogenous urocortins reduce vascular tone and renin-aldosterone/endothelin activity in experimental heart failure
    Miriam T Rademaker
    Christchurch Cardioendocrine Research Group, Department of Medicine, The Christchurch School of Medicine, PO Box 4345, Christchurch, New Zealand
    Eur Heart J 26:2046-54. 2005
    ..To investigate the role of the endogenous urocortin peptides in heart failure (HF) through blockade of the corticotropin-releasing factor receptor 2 (CRF-R2)...
  48. doi request reprint CYP1A1 MSPI (T6235C) gene polymorphism is associated with mortality in acute coronary syndrome patients
    Martin D Jarvis
    Christchurch Cardioendocrine Research Group, Department of Medicine, University of Otago, Christchurch, New Zealand
    Clin Exp Pharmacol Physiol 37:193-8. 2010
    ..853). 4. The results indicate that the homozygous CYP1A1 6235C genotype is associated with greater mortality following the onset of ACS, independent of ethnicity and clinical risk factors, but related to smoking history...
  49. doi request reprint Serial Doppler echocardiography and tissue Doppler imaging in the detection of elevated directly measured left atrial pressure in ambulant subjects with chronic heart failure
    Jay L Ritzema
    Department of Medicine, University of Otago, Christchurch, New Zealand
    JACC Cardiovasc Imaging 4:927-34. 2011
    ....
  50. ncbi request reprint Angiotensin-converting enzyme gene polymorphism interacts with left ventricular ejection fraction and brain natriuretic peptide levels to predict mortality after myocardial infarction
    Barry R Palmer
    Christchurch Cardioendocrine Research Group, Department of Medicine, Christchurch School of Medicine and Health Sciences, Christchurch, New Zealand
    J Am Coll Cardiol 41:729-36. 2003
    ....
  51. doi request reprint N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) trial
    John G Lainchbury
    Department of Medicine, Christchurch Cardioendocrine Research Group, University of Otago, Christchurch, New Zealand
    J Am Coll Cardiol 55:53-60. 2009
    ....
  52. ncbi request reprint Effect of urocortin 1 infusion in humans with stable congestive cardiac failure
    Mark E Davis
    Christchurch Cardioendocrine Research Group, Christchurch School of Medicine and Health Sciences, Christchurch 8001, New Zealand
    Clin Sci (Lond) 109:381-8. 2005
    ..ANP and ghrelin were unchanged, and no haemodynamic or renal effects were seen. In conclusion, a brief intravenous infusion of 50 microg of Ucn 1 stimulates corticotropin and cortisol in male volunteers with stable HF...
  53. pmc Plasma lipids and betaine are related in an acute coronary syndrome cohort
    Michael Lever
    Clinical Biochemistry Unit, Canterbury Health Laboratories, Christchurch, New Zealand
    PLoS ONE 6:e21666. 2011
    ..We aimed to measure the relationships between plasma and urine betaine and plasma lipids, and the effects of lipid-lowering drugs on these...
  54. doi request reprint First identification of circulating prepro-A-type natriuretic peptide (preproANP) signal peptide fragments in humans: initial assessment as cardiovascular biomarkers
    Chris J Pemberton
    Christchurch Cardioendocrine Research Group, Department of Medicine, University of Otago, Christchurch, New Zealand
    Clin Chem 58:757-67. 2012
    ..New biomarkers are needed to assist clinical decision making in cardiovascular disease. We have recently shown that signal peptides may represent a novel biomarker target in cardiovascular diseases...
  55. doi request reprint 2-Hour accelerated diagnostic protocol to assess patients with chest pain symptoms using contemporary troponins as the only biomarker: the ADAPT trial
    Martin Than
    Christchurch Hospital, Christchurch, New Zealand
    J Am Coll Cardiol 59:2091-8. 2012
    ..The purpose of this study was to determine whether a new accelerated diagnostic protocol (ADP) for possible cardiac chest pain could identify low-risk patients suitable for early discharge (with follow-up shortly after discharge)...
  56. ncbi request reprint Plasma amino-terminal pro C-type natriuretic Peptide in the neonate: relation to gestational age and postnatal linear growth
    Timothy C R Prickett
    Department of Medicine, Christchurch School of Medicine and Health Sciences, PO Box 4345, Christchurch Mail Centre, Christchurch 8140, New Zealand
    J Clin Endocrinol Metab 93:225-32. 2008
    ..Whether correlations of NTproCNP with linear growth, as found in children and lambs, apply in neonates is unknown...
  57. ncbi request reprint Direct left atrial pressure monitoring in ambulatory heart failure patients: initial experience with a new permanent implantable device
    Jay Ritzema
    Department of Cardiology, Parkside West, Christchurch Hospital, Private Bag 4710, Christchurch, New Zealand 8001
    Circulation 116:2952-9. 2007
    ..We describe the first human experience with a permanently implantable, direct left atrial pressure (LAP) monitoring system in ambulatory patients with chronic heart failure...
  58. ncbi request reprint Adrenomedullin and the renin-angiotensin-aldosterone system
    Christopher J Charles
    Christchurch Cardioendocrine Research Group, Christchurch School of Medicine, PO Box 4345, Christchurch, New Zealand
    Regul Pept 112:41-9. 2003
    ..Thus, these results clearly point to a role for AM in pressure and volume homeostasis acting, at least in part, by interaction with the renin-angiotensin-aldosterone system (RAAS)...
  59. doi request reprint Skeletal contributions to plasma CNP forms: evidence from regional sampling in growing lambs
    Timothy C R Prickett
    Department of Medicine, University of Otago, Christchurch, New Zealand
    Peptides 30:2343-7. 2009
    ....
  60. ncbi request reprint Adrenomedullin and heart failure
    Miriam T Rademaker
    The Christchurch Cardioendocrine Research Group, Department of Medicine, The Christchurch School of Medicine, PO Box 4345, Christchurch, New Zealand
    Regul Pept 112:51-60. 2003
    ..Manipulation of the AM system holds promise as a therapeutic strategy in cardiac disease...
  61. ncbi request reprint Natriuretic peptides maintain sodium homoeostasis during chronic volume loading post-myocardial infarction in sheep
    Christopher J Charles
    Christchurch Cardioendocrine Research Group, Christchurch School of Medicine and Health Sciences, PO Box 4345, Christchurch, New Zealand
    Clin Sci (Lond) 104:429-36. 2003
    ..This study provides evidence that natriuretic peptides play a pivotal role in preserving volume/electrolyte balance in the early stages of post-MI cardiac dysfunction...
  62. ncbi request reprint Direct cardiac actions of erythropoietin (EPO): effects on cardiac contractility, BNP secretion and ischaemia/reperfusion injury
    Jarkko Piuhola
    Christchurch Cardioendocrine Research Group, University of Otago, Christchurch, New Zealand
    Clin Sci (Lond) 114:293-304. 2008
    ..Thus EPO directly enhances cardiac contractility and BNP secretion and alleviates ischemia/reperfusion injury via ET-1-dependent and -independent mechanisms respectively...
  63. doi request reprint Plasma urocortin 1 in human heart failure
    Sue P Wright
    Department of Medicine, Faculty of Medicine and Health Sciences, University of Auckland, Auckland, New Zealand
    Circ Heart Fail 2:465-71. 2009
    ..We have investigated plasma urocortin 1 as a potential diagnostic marker of heart failure and documented its relationships to symptoms, measures of cardiac function, and concurrent levels of other circulating neurohormones...
  64. ncbi request reprint The effects of medications on circulating levels of cardiac natriuretic peptides
    Richard W Troughton
    Department of Medicine, Christchurch School of Medicine and Health Sciences, Christchurch, New Zealand
    Ann Med 39:242-60. 2007
    ..In the meantime, clinicians need to consider the known effects of medications when interpreting plasma levels of the cardiac natriuretic peptides...
  65. ncbi request reprint Introduction of metoprolol increases plasma B-type cardiac natriuretic peptides in mild, stable heart failure
    Mark E Davis
    The Cardioendocrine Research Group, Christchurch School of Medicine and Health Sciences, Christchurch, New Zealand
    Circulation 113:977-85. 2006
    ....
  66. ncbi request reprint Plasma urocortin 1 in sheep: regional sampling and effects of experimental heart failure
    Christopher J Charles
    Christchurch Cardioendocrine Research Group, Christchurch School of Medicine and Health Sciences, Christchurch, New Zealand
    Peptides 27:1801-5. 2006
    ..This is the first report identifying sources of circulating Ucn-1...
  67. ncbi request reprint Regional sampling and the effects of experimental heart failure in sheep: differential responses in A, B and C-type natriuretic peptides
    Christopher J Charles
    Christchurch Cardioendocrine Research Group, Christchurch School of Medicine and Health Sciences, P O Box 4345, Christchurch, New Zealand
    Peptides 27:62-8. 2006
    ..Circulating levels of CNP and NT-CNP were raised in heart failure but to a much lesser degree than ANP and BNP. There was no evidence of net extraction of CNP or NT-CNP across any tissue bed...
  68. ncbi request reprint Ile164 variant of beta2-adrenoceptor does not influence outcome in heart failure but may interact with beta blocker treatment
    Mathew D Littlejohn
    Department of Pathology and Carney Centre for Pharmacogenomics, University of Otago, Christchurch, PO Box 4345, Christchurch, New Zealand
    Eur J Heart Fail 10:55-9. 2008
    ..The Ile164 variant of the beta2-adrenoceptor has been shown to alter cardiovascular phenotypes and adversely affect survival in heart failure patients...
  69. ncbi request reprint Urocortin 1 exhibits potent inhibition of cardiac sympathetic nerve activity in conscious sheep
    Christopher J Charles
    Christchurch Cardioendocrine Research Group, Christchurch School of Medicine and Health Sciences, Christchurch, New Zealand
    J Hypertens 26:53-60. 2008
    ..Urocortin 1 (Ucn1) and the sympathetic nervous system both participate in cardiac and circulatory regulation, but little is known about their possible interactions...
  70. doi request reprint B-type natriuretic peptide signal peptide circulates in human blood: evaluation as a potential biomarker of cardiac ischemia
    Maithri Siriwardena
    Department of Medicine, University of Otago, Christchurch, New Zealand
    Circulation 122:255-64. 2010
    ..However, there is a clear need to identify circulating, specific biomarkers that can detect cardiac ischemia without necrosis...
  71. ncbi request reprint BNP in hormone-guided treatment of heart failure
    A Mark Richards
    Christchurch Cardioendocrine Research Group, Dept Medicine, Christchurch School of Medicine, Riccarton Avenue, PO Box 4345, Christchurch, New Zealand
    Trends Endocrinol Metab 13:151-5. 2002
    ..This encourages further exploration of hormone guidance of anti-heart failure therapy, which could be extended to patients with preserved ejection fraction, in addition to those with established systolic dysfunction...
  72. ncbi request reprint Images in cardiovascular medicine. Dynamic myocardial ischemia caused by circumflex artery stenosis detected by a new implantable left atrial pressure monitoring device
    Jay L T Ritzema-Carter
    Christchurch Hospital, Christchurch, New Zealand
    Circulation 113:e705-6. 2006
  73. ncbi request reprint Usefulness of serial measurement of N-terminal pro-brain natriuretic peptide plasma levels in asymptomatic patients with aortic stenosis to predict symptomatic deterioration
    Ivor L Gerber
    Department of Cardiology, Auckland City Hospital, Auckland New Zealand
    Am J Cardiol 95:898-901. 2005
    ..Measurement of NT-pro-BNP in addition to clinical assessment and echocardiography may allow more reliable follow-up and timing of valve replacement for aortic stenosis...
  74. ncbi request reprint Prediction of cardiac rhythm 1 year following cardioversion for atrial fibrillation
    Amjad K Hamid
    Department of Medicine, Otago University Christchurch, Christchurch, New Zealand
    N Z Med J 124:48-56. 2011
    ..There is little recent information regarding outcome and its determinants following cardioversion (CV) for atrial fibrillation (AF) or flutter. This study aims to help improve prediction of cardiac rhythm outcome following CV for AF...
  75. ncbi request reprint Coenzyme Q10; an adjunctive therapy for congestive heart failure?
    Sarah L Molyneux
    Biochemistry Unit, Canterbury Health Laboratories, Christchurch, New Zealand
    N Z Med J 122:74-9. 2009
    ..CoQ10 depletion may also be a contributory factor for why statin intervention has not improved outcomes in CHF. There is an emerging evidence base in support of CoQ10 as an adjunctive therapy in CHF...
  76. ncbi request reprint Combined endopeptidase inhibition and adrenomedullin in sheep with experimental heart failure
    Miriam T Rademaker
    Christchurch Cardioendocrine Research Group, Department of Medicine, The Christchurch School of Medicine, Christchurch, New Zealand
    Hypertension 39:93-8. 2002
    ..In conclusion, cotreatment with adrenomedullin and an endopeptidase inhibitor has beneficial hemodynamic and renal effects in heart failure beyond those of either agent separately...
  77. ncbi request reprint Cardiac natriuretic peptides for cardiac health
    Miriam T Rademaker
    Christchurch Cardioendocrine Research Group, Department of Medicine, The Christchurch School of Medicine and Health Sciences, Christchurch, New Zealand
    Clin Sci (Lond) 108:23-36. 2005
    ..The favourable biological properties of the natriuretic peptides have also led to their use as therapeutic agents...
  78. doi request reprint Early dynamic change in high-sensitivity cardiac troponin T in the investigation of acute myocardial infarction
    Sally J Aldous
    Christchurch Hospital, Christchurch, New Zealand
    Clin Chem 57:1154-60. 2011
    ..How much troponin must change has not been specified. We ascertained whether dynamic changes (δ) in high-sensitivity troponin T (hs-TnT) improved diagnostic and prognostic test performance in the emergency department...
  79. doi request reprint B-type natriuretic peptides and echocardiographic measures of cardiac structure and function
    Richard W Troughton
    University Department of Medicine, University of Otago Christchurch, Christchurch, New Zealand
    JACC Cardiovasc Imaging 2:216-25. 2009
    ....
  80. ncbi request reprint BNP for clinical monitoring of heart failure
    Richard W Troughton
    Christchurch School of Medicine and Health Sciences, Christchurch, New Zealand
    Heart Fail Clin 2:333-43. 2006
  81. doi request reprint A randomized trial of the aldosterone-receptor antagonist eplerenone in asymptomatic moderate-severe aortic stenosis
    Ralph A H Stewart
    Green Lane Cardiovascular Service, Auckland City Hospital, Auckland, New Zealand
    Am Heart J 156:348-55. 2008
    ..Effects of eplerenone on LV diastolic function and progression of valve stenosis were also evaluated...
  82. doi request reprint Characterization of NT-proBNP in human urine
    Suetonia C Palmer
    Christchurch Cardioendocrine Research Group, University of Otago Christchurch, New Zealand
    Clin Chem 55:1126-34. 2009
    ..We characterized the molecular forms of urine NT-proBNP detected by immunoassay...
  83. ncbi request reprint Plasma brain natriuretic peptide after long-term treatment for heart failure in general practice
    Graham McGeoch
    Department of Public Health and General Practice, The Christchurch School of Medicine, University of Otago, New Zealand
    Eur J Heart Fail 4:479-83. 2002
    ..Plasma BNP was assessed for its ability to predict echocardiographic abnormality in 100 patients receiving long-term treatment in general practice for a provisional diagnosis of heart failure...
  84. ncbi request reprint Guiding and monitoring of heart failure therapy with NT-ProBNP: concepts and clinical studies
    A Mark Richards
    Department of Medicine, Christchurch Cardioendocrine Research Group, New Zealand
    J Card Fail 11:S34-7. 2005
    ....
  85. doi request reprint Regional clearance of amino-terminal pro-brain natriuretic peptide from human plasma
    Suetonia C Palmer
    Department of Medicine, University of Otago Christchurch, PO Box 4345, Christchurch 8140, New Zealand
    Eur J Heart Fail 11:832-9. 2009
    ..We sought to determine site(s) of production and clearance of plasma NT-proBNP in the human circulation...
  86. ncbi request reprint The neuro-cardio-endocrine response to acute subarachnoid haemorrhage
    Eric A Espiner
    Department of Neurosurgery, Christchurch Hospital, PB 4710, Christchurch, New Zealand
    Clin Endocrinol (Oxf) 56:629-35. 2002
    ....
  87. doi request reprint Outpatient monitoring and treatment of chronic heart failure guided by amino-terminal pro-B-type natriuretic peptide measurement
    Richard W Troughton
    Department of Medicine, Christchurch School of Medicine and Health Sciences, University of Otago, Christchurch, New Zealand
    Am J Cardiol 101:72-5. 2008
    ..Adjustments in treatment and serial clinical follow-up with NT-proBNP retesting should be considered at frequent intervals until biochemical stabilization or achievement of a maximally tolerated medical program...
  88. ncbi request reprint Plasma cardiotrophin-1 is elevated in human hypertension and stimulated by ventricular stretch
    Chris J Pemberton
    Christchurch Cardioendocrine Research Group, Department of Medicine, Christchurch School of Medicine and Health Sciences, University of Otago, 2 Riccarton Avenue, P O Box 4345, Christchurch, New Zealand
    Cardiovasc Res 68:109-17. 2005
    ....
  89. doi request reprint Coenzyme Q10: an independent predictor of mortality in chronic heart failure
    Sarah L Molyneux
    Clinical Biochemistry Unit, Canterbury Health Laboratories, Christchurch, New Zealand
    J Am Coll Cardiol 52:1435-41. 2008
    ..The aim of this study was to investigate the relationship between plasma coenzyme Q(10) (CoQ(10)) and survival in patients with chronic heart failure (CHF)...
  90. ncbi request reprint Beneficial hemodynamic, endocrine, and renal effects of urocortin in experimental heart failure: comparison with normal sheep
    Miriam T Rademaker
    Christchurch Cardioendocrine Research Group, Christchurch School of Medicine, Christchurch, New Zealand
    J Am Coll Cardiol 40:1495-505. 2002
    ..The goal of this study was to determine the bioactivity of urocortin (Ucn) in experimental heart failure (HF)...
  91. ncbi request reprint Adrenomedullin in heart failure
    M Gary Nicholls
    Department of Medicine, Christchurch Hospital, Christchurch, New Zealand
    Hypertens Res 26:S135-40. 2003
    ..An improved understanding of the role of adrenomedullin in heart failure might lead to the development of therapeutic agents acting through adrenomedullin receptors...
  92. ncbi request reprint Urotensin II: evidence for cardiac, hepatic and renal production
    Christopher J Charles
    Christchurch Cardioendocrine Research Group, Christchurch School of Medicine and Health Sciences, PO Box 4345, Christchurch 8001, New Zealand
    Peptides 26:2211-4. 2005
    ..Significant arteriovenous gradients were observed across the heart (36%), liver (40%) and kidney (44%). This is the first report to identify the heart, liver and kidney as sources of UII in the circulation...
  93. ncbi request reprint Effect of beta blockade (carvedilol or metoprolol) on activation of the renin-angiotensin-aldosterone system and natriuretic peptides in chronic heart failure
    Jeffrey W H Fung
    Division of Cardiology, Department of Medicine and Therapeutics, Prince of Wales Hospital, Chinese University of Hong Kong, Hong Kong SAR, China
    Am J Cardiol 92:406-10. 2003
    ..These results indicate that the suppressive effect of beta blockers on PRA in patients with HF taking ACE inhibitors is temporary, and that there is no significant effect on serum aldosterone levels...
  94. ncbi request reprint Associations between plasma natriuretic peptide levels, symptoms, and left ventricular function in patients with chronic aortic regurgitation
    Ivor L Gerber
    Cardiology Department, Green Lane Hospital, Auckland 1030 32, New Zealand
    Am J Cardiol 92:755-8. 2003
    ..In patients with chronic aortic regurgitation, measurement of natriuretic peptide levels may provide information on left ventricular function in addition to echocardiography...
  95. ncbi request reprint N-terminal-pro-B-type natriuretic peptide: universal marker of cardiovascular risk?
    A Mark Richards
    Circulation 112:9-11. 2005
  96. doi request reprint Amino-terminal pro-B-type natriuretic peptide testing in patients with diabetes mellitus and with systemic hypertension
    Per Hildebrandt
    Department of Internal Medicine and Cardiology, Roskilde University Hospital, Roskilde, Denmark
    Am J Cardiol 101:21-4. 2008
    ..In this context, consideration for a more in-depth cardiovascular workup, as well as initiation or intensification of medical therapies with proven benefits might be indicated...
  97. ncbi request reprint A validated clinical and biochemical score for the diagnosis of acute heart failure: the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Acute Heart Failure Score
    Aaron L Baggish
    Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
    Am Heart J 151:48-54. 2006
    ..No method integrating amino-terminal pro-brain natriuretic peptide (NT-proBNP) testing with clinical assessment for the evaluation of patients with suspected acute heart failure (HF) has been described...
  98. ncbi request reprint Routine measurement of natriuretic peptide to guide the diagnosis and management of chronic heart failure
    Richard W Troughton
    Circulation 109:e325-6; author reply e325-6. 2004
  99. ncbi request reprint Usefulness of intermediate amino-terminal pro-brain natriuretic peptide concentrations for diagnosis and prognosis of acute heart failure
    Roland R J van Kimmenade
    Department of Cardiology, University Hospital Maastricht, Maastricht, The Netherlands
    Am J Cardiol 98:386-90. 2006
    ..Mortality rates in subjects with intermediate NT-pro-BNP concentrations are lower than in those with NT-pro-BNP concentrations diagnostic for HF but are higher than in subjects with NT-pro-BNP concentrations less than the gray zone...
  100. ncbi request reprint Plasma B-type natriuretic peptide levels in systolic heart failure: importance of left ventricular diastolic function and right ventricular systolic function
    Richard W Troughton
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, Ohio 44195, USA
    J Am Coll Cardiol 43:416-22. 2004
    ....
  101. ncbi request reprint Coronary sinus and ascending aortic levels of aldosterone, angiotensin II, and B-type natriuretic peptide in patients with aortic stenosis and in patients with coronary heart disease
    Cara A Wasywich
    Cardiology Department, Green Lane Cardiovascular Service, Auckland City Hospital, Auckland, New Zealand
    Am J Cardiol 97:1068-72. 2006
    ....